381 related articles for article (PubMed ID: 18295384)
1. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
[TBL] [Abstract][Full Text] [Related]
2. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
Parkinson C; Thomas KE; Lumley CE
Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
[TBL] [Abstract][Full Text] [Related]
3. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
4. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
5. The value of acute toxicity studies to support the clinical management of overdose and poisoning: a cross-discipline consensus.
Chapman K; Creton S; Kupferschmidt H; Bond GR; Wilks MF; Robinson S
Regul Toxicol Pharmacol; 2010 Dec; 58(3):354-9. PubMed ID: 20627115
[TBL] [Abstract][Full Text] [Related]
6. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
8. What have we learned from pre-clinical juvenile toxicity studies?
Bailey GP; Mariën D
Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432
[TBL] [Abstract][Full Text] [Related]
9. Estimation of acute oral toxicity using the No Observed Adverse Effect Level (NOAEL) from the 28 day repeated dose toxicity studies in rats.
Bulgheroni A; Kinsner-Ovaskainen A; Hoffmann S; Hartung T; Prieto P
Regul Toxicol Pharmacol; 2009 Feb; 53(1):16-9. PubMed ID: 18977273
[TBL] [Abstract][Full Text] [Related]
10. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
[TBL] [Abstract][Full Text] [Related]
11. The European regulatory experience.
Lewis JA
Stat Med; 2002 Oct; 21(19):2931-8. PubMed ID: 12325109
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
13. Juvenile animal toxicity study designs to support pediatric drug development.
Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
[TBL] [Abstract][Full Text] [Related]
14. Concordance of the toxicity of pharmaceuticals in humans and in animals.
Olson H; Betton G; Robinson D; Thomas K; Monro A; Kolaja G; Lilly P; Sanders J; Sipes G; Bracken W; Dorato M; Van Deun K; Smith P; Berger B; Heller A
Regul Toxicol Pharmacol; 2000 Aug; 32(1):56-67. PubMed ID: 11029269
[TBL] [Abstract][Full Text] [Related]
15. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
16. Pre- and postnatal developmental toxicity study design for pharmaceuticals.
Bailey GP; Wise LD; Buschmann J; Hurtt M; Fisher JE
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):437-45. PubMed ID: 20025040
[TBL] [Abstract][Full Text] [Related]
17. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
Gorodetzky CW; Grudzinskas C
Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
[TBL] [Abstract][Full Text] [Related]
18. Evidence used for approval of new drugs.
Botstein P
Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042
[TBL] [Abstract][Full Text] [Related]
19. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
[TBL] [Abstract][Full Text] [Related]
20. Safety evaluation to support First-In-Man investigations II: toxicology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
